Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma
1 other identifier
interventional
117
1 country
1
Brief Summary
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2007
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 15, 2012
CompletedFirst Posted
Study publicly available on registry
October 18, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedMarch 29, 2017
March 1, 2017
8.8 years
October 15, 2012
March 27, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
clinical outcomes
To evaluate biochemical failure-free survival (BCFFS)
up to 5years from a initial follow-up
Secondary Outcomes (3)
acute toxicity
up to 5years from a initial follow-up
late toxicity
up to 5years from a initial follow-up
overall survival
up to 5years from a initial follow-up
Study Arms (4)
Arm 1
EXPERIMENTAL27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
Arm 2
EXPERIMENTAL27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
Arm 3
EXPERIMENTAL27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
Arm 4
EXPERIMENTAL27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
Interventions
hypofractionation study using proton beam therapy for prostate adenocarcinoma
Eligibility Criteria
You may qualify if:
- Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2 Signed study specific informed consent prior to study entry
You may not qualify if:
- Postoperative residual or recurrent tumor Evidence of distant metastases Previous irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National cancer center, korea
Goyang-si, Gyeonggi-do, 411-769, South Korea
Related Publications (1)
Ha B, Cho KH, Lee KH, Joung JY, Kim YJ, Lee SU, Kim H, Suh YG, Moon SH, Lim YK, Jeong JH, Kim H, Park WS, Kim SH. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation. Radiat Oncol. 2019 Jan 10;14(1):4. doi: 10.1186/s13014-019-1210-7.
PMID: 30630500DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
kwan ho cho, M.D.
National Cancer Center, Korea
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.
Study Record Dates
First Submitted
October 15, 2012
First Posted
October 18, 2012
Study Start
March 1, 2007
Primary Completion
December 1, 2015
Study Completion
December 1, 2015
Last Updated
March 29, 2017
Record last verified: 2017-03